...
INCYLARGE

Incyte Corporation

HealthcareBiotechnology
$101.27
$0.01(+1.18%)
52W$53.56
$112.29
FinancialsValuationvs RVMD
Updated Mar 2, 12:00 AM
RSI45
RS Rating71/99
Beta0.61
Volatility35%
F-Score7/9
Mkt Cap$20.1B
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Incyte Corporation shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is moderate (RS Rating: 71), indicating performance broadly in line with the market. Earnings growth of 43% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.

Relative Strength
71
out of 99
Average
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
0.61
vs S&P 500
DEFENSIVE
52W Position
81%
from 52W low
Near High
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$102.43
50 SMA > 100 SMA$99.70
100 SMA > 150 SMA$94.24
150 SMA > 200 SMA$87.58

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$101.97-0.69%BELOW
50 SMA$102.43-1.13%BELOW
100 SMA$99.70+1.58%ABOVE
150 SMA$94.24+7.46%ABOVE
200 SMA$87.58+15.63%ABOVE

Price Performance

1D+1.2%
1W+0.4%
1M+0.1%
3M-3.1%
6M+21.0%
YTD-0.1%
1Y+37.8%
3Y+9.6%
52-Week Trading Range81% from low
$101.27
52W Low$53.56
52W High$112.29

Technical Indicators

RSI (14)NEUTRAL
44.9
305070
VCP ScoreWARM
8/10
Base depth: 18.5%

Risk Profile

Beta
0.61
52W Vol
35%
ATR
$3.38
Max DD (1Y)
-25%

Volume Analysis

Today
101
50D Avg
1.64M
Vol Ratio
0.00x
Liquidity
LIQUID

Earnings Momentum

Q1'25+7%
$0.80
Q2'25+200%
$2.04
Q3'25+291%
$2.11
Q4'25+43%
$1.46
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+21.17%
5 Years:+14.03%
3 Years:+14.84%
TTM:+21.22%

Compounded Profit Growth

10 Years:+70.99%
5 Years:—
3 Years:+61.56%
TTM:+22.74%

Stock Price CAGR

10 Years:+3.26%
5 Years:+4.93%
3 Years:+9.57%
1 Year:+37.78%

Return on Equity

10Y Avg:10.1%
5Y Avg:16.2%
3Y Avg:14.4%
Last Year:24.9%

Key Metrics

Market Cap$20.1B
Gross Margin91.5%
Net Margin25.0%
Piotroski F-Score7/9

More INCY Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

INCY vs RVMDRVMDGMABEXELIBRX

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 71 meansINCY outperformed 71% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.61 means 39% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 7/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 8/10 with WARM status.

Frequently Asked Questions

Is INCY in an uptrend right now?

INCY has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is INCY overbought or oversold?

INCY's RSI (14) is 45. The stock is in neutral territory, neither overbought nor oversold.

Is INCY outperforming the market?

INCY has a Relative Strength (RS) Rating of 71 out of 99. INCY is performing about average compared to the market.

Where is INCY in its 52-week range?

INCY is trading at $101.27, which is 90% of its 52-week high ($112.29) and 81% above its 52-week low ($53.56).

How volatile is INCY?

INCY has a Beta of 0.61 and 52-week volatility of 35%. It's less volatile than the S&P 500 - generally more stable.